<\/p>\n
A pioneering trial of umbilical\u2011cord derived mesenchymal stromal cells has eased symptoms for some children with recessive dystrophic epidermolysis bullosa, improving wound healing and everyday life for participants such as 12\u2011year\u2011old Gabrielius \u2014 though clinicians and patient groups stress the need for longer follow\u2011up and independent review before wider use.<\/p>\n<\/div>\n
Gabrielius Misurenkovas, a 12\u2011year\u2011old from east London who has lived with the devastating fragility of recessive dystrophic epidermolysis bullosa (RDEB) since infancy, has seen many of the daily burdens of his condition ease after taking part in a pioneering stem\u2011cell infusion trial. According to reporting on the study, the boy\u2019s wounds healed faster, his skin was less inflamed and itchy, and he gained small but meaningful freedoms \u2014 cycling on grass and playing football with friends \u2014 that were previously impossible without risk of painful blistering. These improvements prompted hope among clinicians and families that the therapy could offer the first disease\u2011modifying effect for some children with RDEB. (This account is based on the original clinical report and hospital commentary.) <\/p>\n
RDEB is a genetic disorder caused by mutations in COL7A1 that impair production of type VII collagen, the protein that binds the skin\u2019s layers together. The condition leaves skin extraordinarily fragile: minor friction or pressure can cause blistering, deep wounds and scarring, and ongoing inflammation. Over time many patients develop aggressive cutaneous squamous cell carcinoma (cSCC) at a young age, a complication that is a leading cause of death in RDEB. Clinicians and patient groups have therefore long sought therapies that not only relieve symptoms but might reduce long\u2011term cancer risk by limiting chronic injury and inflammation. <\/p>\n
The therapy at the centre of Gabrielius\u2019s care is CORDStrom, an off\u2011the\u2011shelf product of umbilical\u2011cord derived mesenchymal stromal cells (MSC) delivered intravenously. The treatment was evaluated in MissionEB, a randomised, double\u2011blind, placebo\u2011controlled crossover trial run at Great Ormond Street Hospital and Birmingham Children\u2019s Hospital. Trial documentation and coordination information describe a rigorous protocol with an internal dose\u2011de\u2011escalation safety phase, blinded treatment and a planned 12\u2011month open\u2011label extension to monitor longer\u2011term effects. The study recruited children with intermediate or severe forms of RDEB and used validated clinical measures to assess outcomes. <\/p>\n
In practice the therapy was administered as a short intravenous infusion over roughly 10\u201315 minutes. The randomised scheme meant roughly half of participants received two infusions of the cell product over a two\u2011week period while the others received placebo; after a nine\u2011month wash\u2011out the groups crossed over so each child had the opportunity to receive the active treatment. The published protocol specifies dosing in the range of 2\u20133\u00d710^6 cells per kg, with safety monitoring and pre\u2011defined outcome measures, including change in disease activity at three months as a primary endpoint. <\/p>\n
Early results reported by investigators and by the company supplying the cells indicate age\u2011 and severity\u2011dependent benefits. Families and clinicians documented reductions in itch, improved wound healing and better skin scores, with the most notable gains seen in younger children and those with the intermediate form of RDEB. Parents reported improvements in everyday wellbeing such as less disturbed sleep because dressings were needed less often, and children described being able to try activities they had previously avoided. The study authors emphasised that the therapy was generally well tolerated by the young participants. <\/p>\n
The manufacturer, INmune Bio, characterised the MissionEB data as showing a favourable benefit\u2013risk profile and said there were no serious treatment\u2011related adverse events. The company has signalled its intent to pursue regulatory approvals in multiple jurisdictions and noted orphan and rare paediatric designations from US regulators, while also describing a data\u2011licence arrangement with Great Ormond Street Hospital and plans for continued supply to trial participants. These claims come from the company\u2019s own press materials and should be understood as the company\u2019s position while regulatory review and independent peer assessment continue. <\/p>\n
Families\u2019 voices have been prominent in trial reports. Gabrielius said he joined the trial hoping to be able to \u201cdo more of the things I enjoy, like playing football and spending time with my friends,\u201d a comment reported in the initial coverage. His mother, Jolita Cekaviciene, told reporters that her son \u201cdid really well on the trial\u201d and described practical benefits such as reduced itch and less frequent dressing changes. Lead clinicians, including the trial\u2019s paediatric dermatologist, highlighted the safety signal and the potential for early, regular infusions to reduce inflammation and, in time, possibly lower the future risk of squamous cell carcinoma \u2014 a cautious formulation that reflects the need for longer follow\u2011up. <\/p>\n
Caution remains essential. The MissionEB study, while randomised and placebo\u2011controlled, involved a relatively small cohort and uses a crossover design; the principal published protocol sets the primary efficacy read\u2011out at three months and plans a 12\u2011month open\u2011label extension. That extension is intended to capture longer\u2011term safety and durability of effect, which will be critical to determining whether repeated MSC infusions can meaningfully alter the disease trajectory and potential cancer risk. Independent reviewers and patient groups stress the need for larger, longer studies and for regulatory scrutiny before any widespread adoption. <\/p>\n
For families and the rare disease community the early findings represent guarded optimism. Patient charities and funders that supported MissionEB described the results as an important step toward making MSC infusions part of routine clinical care for children with RDEB, but all parties and clinicians emphasise that further follow\u2011up, publication of full peer\u2011reviewed results and regulatory evaluation are required before that promise can be realised. In the meantime the trial offers a tangible improvement in daily life for some participants and a clearer roadmap for subsequent research. <\/p>\n